The BFAST trial is an ongoing six-cohort study prospectively evaluating the relationship between blood-based biomarkers (ALK, RET, ROS1, BRAF, EGFR exon 20, blood tumor mutational burden (bTMB)) and clinical activity of target or immune-therapy in first-line NSCLC setting patients who only underwent NGS for the detection of actionable genetic alterations [58]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.